Compare PRGO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | PGEN |
|---|---|---|
| Founded | 1887 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2013 | 2013 |
| Metric | PRGO | PGEN |
|---|---|---|
| Price | $10.25 | $5.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $19.33 | $8.33 |
| AVG Volume (30 Days) | 3.1M | ★ 4.0M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $800,000.00 | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $1.02 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.23 | $1.57 |
| 52 Week High | $28.22 | $6.04 |
| Indicator | PRGO | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 58.35 |
| Support Level | $9.42 | $3.96 |
| Resistance Level | $11.72 | $6.04 |
| Average True Range (ATR) | 0.48 | 0.28 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 31.94 | 82.95 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.